Wall Street analysts expect RTI Surgical, Inc. (NASDAQ:RTIX) to post $70.16 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for RTI Surgical’s earnings. The highest sales estimate is $70.82 million and the lowest is $69.49 million. RTI Surgical posted sales of $71.35 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 1.7%. The business is expected to report its next quarterly earnings results on Thursday, February 22nd.

According to Zacks, analysts expect that RTI Surgical will report full year sales of $70.16 million for the current financial year, with estimates ranging from $278.40 million to $279.56 million. For the next year, analysts anticipate that the company will post sales of $282.10 million per share, with estimates ranging from $281.94 million to $282.26 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that that provide coverage for RTI Surgical.

RTI Surgical (NASDAQ:RTIX) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported $0.01 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.01. The company had revenue of $66.69 million for the quarter, compared to analysts’ expectations of $65.63 million. RTI Surgical had a return on equity of 2.29% and a net margin of 1.01%. The business’s revenue for the quarter was up .2% on a year-over-year basis.

A number of research firms have recently weighed in on RTIX. BidaskClub cut RTI Surgical from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Zacks Investment Research raised RTI Surgical from a “sell” rating to a “hold” rating in a report on Friday, October 13th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cigna Investments Inc. New acquired a new position in shares of RTI Surgical during the second quarter valued at approximately $105,000. Prudential Financial Inc. acquired a new position in shares of RTI Surgical during the third quarter valued at approximately $111,000. Citadel Advisors LLC increased its stake in shares of RTI Surgical by 85.7% during the third quarter. Citadel Advisors LLC now owns 26,786 shares of the medical equipment provider’s stock valued at $122,000 after acquiring an additional 12,361 shares during the period. Citigroup Inc. increased its stake in shares of RTI Surgical by 2,850.1% during the second quarter. Citigroup Inc. now owns 21,152 shares of the medical equipment provider’s stock valued at $124,000 after acquiring an additional 20,435 shares during the period. Finally, First Quadrant L P CA acquired a new position in shares of RTI Surgical during the second quarter valued at approximately $137,000. 68.37% of the stock is currently owned by institutional investors.

Shares of RTI Surgical (NASDAQ:RTIX) opened at $4.95 on Friday. The firm has a market capitalization of $288.62, a P/E ratio of 118.75, a PEG ratio of 6.33 and a beta of 1.73. The company has a current ratio of 3.34, a quick ratio of 1.21 and a debt-to-equity ratio of 0.25. RTI Surgical has a twelve month low of $2.81 and a twelve month high of $6.00.

TRADEMARK VIOLATION WARNING: “RTI Surgical, Inc. (RTIX) Expected to Post Quarterly Sales of $70.16 Million” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/25/rti-surgical-inc-rtix-expected-to-post-quarterly-sales-of-70-16-million.html.

About RTI Surgical

RTI Surgical, Inc is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties.

Get a free copy of the Zacks research report on RTI Surgical (RTIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RTI Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.